PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report

Stephen X. Skapek, James Anderson, Frederic G. Barr, Julia A. Bridge, Julie M. Gastier-Foster, David M. Parham, Erin R. Rudzinski, Timothy Triche, Douglas S. Hawkins

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Background: Rhabdomyosarcoma (RMS) is divided into two major histological subtypes: alveolar (ARMS) and embryonal (ERMS), with most ARMS expressing one of two oncogenic genes fusing PAX3 or PAX7 with FOXO1 (P3F and P7F, respectively). The Children's Oncology Group (COG) carried out a multi-institutional clinical trial to evaluate the prognostic value of PAX-FOXO1 fusion status. Methods: Study participants were treated on COG protocol D9803 for intermediate risk ARMS or ERMS using multi-agent chemotherapy, radiotherapy, and surgery. Central diagnostic pathology review and molecular testing for fusion genes were carried out on prospectively collected specimens. Event-free (EFS) and overall survival (OS) at 5 years were correlated with histological subtype and PAX-FOXO1 status. Results: Of 616 eligible D9803 enrollees, 434 cases had adequate clinical, molecular, and pathology data for definitive classification as ERMS, ARMS P3F+ or P7F+, or ARMSn (without detectable fusion). EFS was worse for those with ARMS P3F+ (54%) and P7F+ (65%) than those with ERMS (77%; P<0.001). EFS for ARMSn and ERMS were not statistically different (90% vs. 77%, P=0.15). ARMS P3F+ had poorer OS (64%) than ARMS P7F+ (87%), ARMSn (89%), and ERMS (82%; P=0.006). Conclusions: ARMSn has an outcome similar to ERMS and superior EFS compared to ARMS with either P3F or P7F, when given therapy designed for children with intermediate risk RMS. This prospective analysis supports incorporation of PAX-FOXO1 fusion status into risk stratification and treatment allocation.

Original languageEnglish (US)
Pages (from-to)1411-1417
Number of pages7
JournalPediatric Blood and Cancer
Volume60
Issue number9
DOIs
StatePublished - Sep 1 2013

Fingerprint

Rhabdomyosarcoma
Molecular Pathology
Clinical Pathology
Gene Fusion
Radiotherapy
Clinical Trials
Drug Therapy
Therapeutics
Genes

Keywords

  • PAX-FOXO1
  • Rhabdomyosarcoma
  • Survival

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Skapek, S. X., Anderson, J., Barr, F. G., Bridge, J. A., Gastier-Foster, J. M., Parham, D. M., ... Hawkins, D. S. (2013). PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report. Pediatric Blood and Cancer, 60(9), 1411-1417. https://doi.org/10.1002/pbc.24532

PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma : A children's oncology group report. / Skapek, Stephen X.; Anderson, James; Barr, Frederic G.; Bridge, Julia A.; Gastier-Foster, Julie M.; Parham, David M.; Rudzinski, Erin R.; Triche, Timothy; Hawkins, Douglas S.

In: Pediatric Blood and Cancer, Vol. 60, No. 9, 01.09.2013, p. 1411-1417.

Research output: Contribution to journalArticle

Skapek, SX, Anderson, J, Barr, FG, Bridge, JA, Gastier-Foster, JM, Parham, DM, Rudzinski, ER, Triche, T & Hawkins, DS 2013, 'PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report', Pediatric Blood and Cancer, vol. 60, no. 9, pp. 1411-1417. https://doi.org/10.1002/pbc.24532
Skapek, Stephen X. ; Anderson, James ; Barr, Frederic G. ; Bridge, Julia A. ; Gastier-Foster, Julie M. ; Parham, David M. ; Rudzinski, Erin R. ; Triche, Timothy ; Hawkins, Douglas S. / PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma : A children's oncology group report. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 9. pp. 1411-1417.
@article{6a677437a8ff43a3aa952347ad870707,
title = "PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report",
abstract = "Background: Rhabdomyosarcoma (RMS) is divided into two major histological subtypes: alveolar (ARMS) and embryonal (ERMS), with most ARMS expressing one of two oncogenic genes fusing PAX3 or PAX7 with FOXO1 (P3F and P7F, respectively). The Children's Oncology Group (COG) carried out a multi-institutional clinical trial to evaluate the prognostic value of PAX-FOXO1 fusion status. Methods: Study participants were treated on COG protocol D9803 for intermediate risk ARMS or ERMS using multi-agent chemotherapy, radiotherapy, and surgery. Central diagnostic pathology review and molecular testing for fusion genes were carried out on prospectively collected specimens. Event-free (EFS) and overall survival (OS) at 5 years were correlated with histological subtype and PAX-FOXO1 status. Results: Of 616 eligible D9803 enrollees, 434 cases had adequate clinical, molecular, and pathology data for definitive classification as ERMS, ARMS P3F+ or P7F+, or ARMSn (without detectable fusion). EFS was worse for those with ARMS P3F+ (54{\%}) and P7F+ (65{\%}) than those with ERMS (77{\%}; P<0.001). EFS for ARMSn and ERMS were not statistically different (90{\%} vs. 77{\%}, P=0.15). ARMS P3F+ had poorer OS (64{\%}) than ARMS P7F+ (87{\%}), ARMSn (89{\%}), and ERMS (82{\%}; P=0.006). Conclusions: ARMSn has an outcome similar to ERMS and superior EFS compared to ARMS with either P3F or P7F, when given therapy designed for children with intermediate risk RMS. This prospective analysis supports incorporation of PAX-FOXO1 fusion status into risk stratification and treatment allocation.",
keywords = "PAX-FOXO1, Rhabdomyosarcoma, Survival",
author = "Skapek, {Stephen X.} and James Anderson and Barr, {Frederic G.} and Bridge, {Julia A.} and Gastier-Foster, {Julie M.} and Parham, {David M.} and Rudzinski, {Erin R.} and Timothy Triche and Hawkins, {Douglas S.}",
year = "2013",
month = "9",
day = "1",
doi = "10.1002/pbc.24532",
language = "English (US)",
volume = "60",
pages = "1411--1417",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma

T2 - A children's oncology group report

AU - Skapek, Stephen X.

AU - Anderson, James

AU - Barr, Frederic G.

AU - Bridge, Julia A.

AU - Gastier-Foster, Julie M.

AU - Parham, David M.

AU - Rudzinski, Erin R.

AU - Triche, Timothy

AU - Hawkins, Douglas S.

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Background: Rhabdomyosarcoma (RMS) is divided into two major histological subtypes: alveolar (ARMS) and embryonal (ERMS), with most ARMS expressing one of two oncogenic genes fusing PAX3 or PAX7 with FOXO1 (P3F and P7F, respectively). The Children's Oncology Group (COG) carried out a multi-institutional clinical trial to evaluate the prognostic value of PAX-FOXO1 fusion status. Methods: Study participants were treated on COG protocol D9803 for intermediate risk ARMS or ERMS using multi-agent chemotherapy, radiotherapy, and surgery. Central diagnostic pathology review and molecular testing for fusion genes were carried out on prospectively collected specimens. Event-free (EFS) and overall survival (OS) at 5 years were correlated with histological subtype and PAX-FOXO1 status. Results: Of 616 eligible D9803 enrollees, 434 cases had adequate clinical, molecular, and pathology data for definitive classification as ERMS, ARMS P3F+ or P7F+, or ARMSn (without detectable fusion). EFS was worse for those with ARMS P3F+ (54%) and P7F+ (65%) than those with ERMS (77%; P<0.001). EFS for ARMSn and ERMS were not statistically different (90% vs. 77%, P=0.15). ARMS P3F+ had poorer OS (64%) than ARMS P7F+ (87%), ARMSn (89%), and ERMS (82%; P=0.006). Conclusions: ARMSn has an outcome similar to ERMS and superior EFS compared to ARMS with either P3F or P7F, when given therapy designed for children with intermediate risk RMS. This prospective analysis supports incorporation of PAX-FOXO1 fusion status into risk stratification and treatment allocation.

AB - Background: Rhabdomyosarcoma (RMS) is divided into two major histological subtypes: alveolar (ARMS) and embryonal (ERMS), with most ARMS expressing one of two oncogenic genes fusing PAX3 or PAX7 with FOXO1 (P3F and P7F, respectively). The Children's Oncology Group (COG) carried out a multi-institutional clinical trial to evaluate the prognostic value of PAX-FOXO1 fusion status. Methods: Study participants were treated on COG protocol D9803 for intermediate risk ARMS or ERMS using multi-agent chemotherapy, radiotherapy, and surgery. Central diagnostic pathology review and molecular testing for fusion genes were carried out on prospectively collected specimens. Event-free (EFS) and overall survival (OS) at 5 years were correlated with histological subtype and PAX-FOXO1 status. Results: Of 616 eligible D9803 enrollees, 434 cases had adequate clinical, molecular, and pathology data for definitive classification as ERMS, ARMS P3F+ or P7F+, or ARMSn (without detectable fusion). EFS was worse for those with ARMS P3F+ (54%) and P7F+ (65%) than those with ERMS (77%; P<0.001). EFS for ARMSn and ERMS were not statistically different (90% vs. 77%, P=0.15). ARMS P3F+ had poorer OS (64%) than ARMS P7F+ (87%), ARMSn (89%), and ERMS (82%; P=0.006). Conclusions: ARMSn has an outcome similar to ERMS and superior EFS compared to ARMS with either P3F or P7F, when given therapy designed for children with intermediate risk RMS. This prospective analysis supports incorporation of PAX-FOXO1 fusion status into risk stratification and treatment allocation.

KW - PAX-FOXO1

KW - Rhabdomyosarcoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84879431387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879431387&partnerID=8YFLogxK

U2 - 10.1002/pbc.24532

DO - 10.1002/pbc.24532

M3 - Article

C2 - 23526739

AN - SCOPUS:84879431387

VL - 60

SP - 1411

EP - 1417

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 9

ER -